MAIA — Maia Biotechnology Income Statement
0.000.00%
Last trade - 00:00- $42.23m
- $32.09m
Annual income statement for Maia Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.91 | 10 | 16.2 | 20.2 | 17 |
| Operating Profit | -6.91 | -10 | -16.2 | -20.2 | -17 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.96 | -12.6 | -15.8 | -19.8 | -23.3 |
| Net Income After Taxes | -6.96 | -12.6 | -15.8 | -19.8 | -23.3 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.64 | -12.5 | -15.8 | -19.8 | -23.3 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.64 | -12.5 | -16.2 | -19.8 | -23.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.63 | -0.963 | -1.75 | -1.49 | -1.05 |
| Dividends per Share |